1. Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

   • Sunad Rangarajan
   • Morgan L. Locy
   • Victor J. Thannickal

   Current Opinion 04 January 2016 Pages: 291 - 300

   

2. Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease

   • Lidia Bakota
   • Roland Brandt

   Leading Article Open access 04 January 2016 Pages: 301 - 313

   

3. What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

   • Working Group Nientemale DEI
   • R. Vellucci
   • P. Romualdi

   Therapy in Practice Open access 11 January 2016 Pages: 315 - 330

   

4. Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy

   • Nick van Es
   • Suzanne M. Bleker
   • Marcello Di Nisio

   Review Article 04 January 2016 Pages: 331 - 341

   

5. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis

   • Roy A. Pleasants
   • Tiansheng Wang
   • James F. Donohue

   Review Article 11 January 2016 Pages: 343 - 361

   

6. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

   • Hannah A. Blair
   • Gillian M. Keating

   Adis Drug Evaluation 28 January 2016 Pages: 363 - 374

7. Pembrolizumab: A Review in Advanced Melanoma

   • Emma D. Deeks

   Adis Drug Evaluation 04 February 2016 Pages: 375 - 386

   

8. Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction

   • Paul L. McCormack

   Adis Drug Evaluation 12 February 2016 Pages: 387 - 396

   

9. Elotuzumab: First Global Approval

   • Anthony Markham

   AdisInsight Report 26 January 2016 Pages: 397 - 403

   

10. Ixazomib: First Global Approval

    • Matt Shirley

    AdisInsight Report 04 February 2016 Pages: 405 - 411

    

11. Selexipag: First Global Approval

    • Lesley J. Scott

    AdisInsight Report 04 February 2016 Pages: 413 - 418

    

12. Erratum to: Cariprazine: First Global Approval

    • Paul L. McCormack

    Erratum 03 February 2016 Pages: 419 - 419